Coave Therapeutics, a France-based gene therapy company, has appointed Olivier Danos and Frederic Chereau as independent non-executive directors. Dr Danos has also been named scientific advisor to the company. Dr Danos is chief scientific offer at RegenxBio Inc which is developing gene therapies for retinal, neurodegenerative and metabolic diseases. Mr Chereau is chief executive of LogicBio Therapeutics Inc, a clinical stage genetic medicines company working on gene editing and delivery platforms for the treatment of rare diseases.
Coave Therapeutics announced the appointments on 12 October 2021.
Copyright 2021 Evernow Publishing Ltd